Sera Prognostics, Inc.

Sera Prognostics, Inc.

SERA·NASDAQ

$2.22

+8.3%
HealthcareMedical - Diagnostics & Research

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

At a Glance

Live Snapshot
Market Cap$84.78M
EPS-0.6700
P/E Ratio-3.31
Earnings Date08/05/2026

sera

Operating Income

Last Annual Value

-36.50M

3-Year CAGR

7%

5-Year CAGR

-15%

10-Year CAGR

-8%

Sera Prognostics, Inc.

Sera Prognostics, Inc. Competitors Analysis of Operating Income

SERA · NASDAQ
CompanyOperating Income
CAGR 3Y
CAGR 5Y
CAGR 10Y
-36.50M
N/AN/AN/A 
-47.39M
N/AN/AN/A
-6.45M
N/AN/AN/A
-39.70M
N/AN/AN/A
DCGO logo
DocGo Inc.
NASDAQ:DCGO
-89.16M
N/AN/AN/A
-42.44M
N/AN/AN/A
-30.58M
N/AN/AN/A
-55.97M
N/AN/AN/A
-31.22M
N/AN/AN/A
-49.64M
N/AN/AN/A
-31.80M
N/AN/AN/A
Sera Prognostics, Inc.

Sera Prognostics, Inc. Fair Value Envelope

SERA · NASDAQ

Our analysis suggests that SERA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.22, this represents a potential HIDDEN relative to our calculated worth for Sera Prognostics, Inc..

Intrinsic Value
Current Price: $2.22